GeneDx is a genomic diagnostics company focused on diagnosing rare genetic diseases, primarily in pediatric patients. Its core products are exome and genome sequencing tests — ExomeDx and GenomeDx — which analyze a patient's DNA to identify disease-causing genetic variants. Clinicians order these tests when patients present with complex, unexplained symptoms like developmental delay, epilepsy, or autism. GeneDx also offers ultraRapid whole genome sequencing that delivers results in as few as 48 hours, targeted at critically ill infants in NICUs. The company generates revenue by charging for diagnostic test reports, billing insurance payers — commercial and Medicaid — and collecting reimbursement per test. Revenue is driven by test volume, average reimbursement per test, and cost per test. GeneDx holds roughly 80% market share among U.S. clinical geneticists. Growth opportunities include deepening penetration with pediatric neurologists, expanding into NICUs via enterprise sales and hospital EMR integrations, entering the general pediatrician market following updated AAP guidelines recommending exome/genome sequencing as a first-line test, and longer-term, genomic newborn screening. GeneDx's key competitive asset is GeneDx Infinity, a proprietary rare disease dataset built over 25 years, containing over 1 million exomes and genomes and more than 8 million phenotypic data points. A larger dataset improves diagnostic accuracy, creating a flywheel where more tests lead to better interpretation, which attracts more clinicians. GeneDx also acquired Fabric Genomics in 2025, a cloud-based genomic interpretation software platform that enables international expansion by licensing GeneDx's interpretation capabilities to hospitals and labs that sequence locally.